米国の抗毒素市場規模、シェア、動向分析レポート：種別、タイプ別、作用機序別、最終用途別、セグメント別予測、2025年～2030年

米国の抗毒素市場概要

米国の抗毒素市場規模は2024年に4億2,450万米ドルと推定され、2025～2030年にかけてCAGR 8.0%で成長し、2030年には6億7,000万米ドルに達すると予測されます。市場は、特にヘビや昆虫による毒咬傷や毒刺傷の発生率の上昇により拡大しています。

都市化、森林伐採、気候変動がこれらの動物の生息地に影響を与え、毒を持つ種と人間との相互作用の増加に拍車をかけています。この動向は、毒物による死亡事故や長期的な健康合併症を減らすための効果的な毒物治療の必要性を高め、米国の毒物治療産業を牽引しています。

バイオテクノロジーの進歩は市場成長に大きく貢献しています。モノクローナル抗体ベース抗ヴェノム薬や組換えDNA技術などの開発により、より強力で安全な標的療法が開発されています。このような技術革新により、治療成績が向上し、製造コストが削減されるため、抗ベノムをより身近なものとすることができます。特に米国では、製薬会社や研究機関による継続的な研究開発努力が、技術革新を促進し、特定の毒タイプに合わせた先進的抗毒素の導入を促進しています。

米国市場は、緊急時に迅速な抗毒素治療へのアクセスを可能にする強固なヘルスケアシステムの恩恵を受けています。屋外でのレクリエーション活動の普及や、野生生物の生息地への市場の開拓により、毒を持つ生物に遭遇する可能性が高まり、市場の需要を牽引しています。さらに、主要な産業参入企業の存在と、医薬品イノベーションに対する政府の継続的な支援が、市場の成長展望を強化しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の抗毒素市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 米国の抗毒素市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析
• 米国の抗毒素市場：パイプライン分析

第4章 米国の抗毒素市場：種別、推定・動向分析

• 種セグメントダッシュボード
• 米国の抗毒素市場：種変動分析
• 米国の抗毒素市場規模と動向分析（種別、2018～2030年）
• ヘビ
  • コモンコブラ
  • コモンクレート
  • ラッセル・バイパー
  • その他
• サソリ
• クモ
• その他

第5章 米国の抗毒素市場：タイプ別、推定・動向分析

• タイプセグメントダッシュボード
• 米国の抗毒素市場：タイプ変動分析
• 米国の抗毒素市場規模と動向分析（タイプ別、2018～2030年）
• 多価
• 一価

第6章 米国の抗毒素市場：作用機序別、推定・動向分析

• 作用機序セグメントダッシュボード
• 米国の抗毒素市場：作用機序変動分析
• 米国の抗毒素市場規模と動向分析（作用機序別、2018～2030年）
• 細胞毒性
• 神経毒性
• 血液毒性
• 心臓毒性
• 筋毒性
• その他

第7章 米国の抗毒素市場：最終用途別、推定・動向分析

• 最終用途セグメントダッシュボード
• 米国の抗毒素市場：最終用途変動分析
• 米国の抗毒素市場規模と動向分析（最終用途別、2018～2030年）
• 病院
• クリニック
• 外来手術センター

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要企業のヒートマップ分析、2024年
• 企業プロファイル
  • Boehringer Ingelheim
  • CSL Limited
  • Merck & Co., Inc.
  • Pfizer, Inc.

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. anti-venom market, by species, 2018 - 2030 (USD Million)
• Table 3 U.S. anti-venom market, by snake 2018 - 2030 (USD Million)
• Table 4 U.S. anti-venom market, by type 2018 - 2030 (USD Million)
• Table 5 U.S. anti-venom market, by mode of action 2018 - 2030 (USD Million)
• Table 6 U.S. anti-venom market, by end use 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. anti-venom market: market outlook
• Fig. 10 U.S. anti-venom competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 U.S. anti-venom market driver impact
• Fig. 16 U.S. anti-venom market restraint impact
• Fig. 17 U.S. anti-venom market strategic initiatives analysis
• Fig. 18 U.S. anti-venom market: Species movement analysis
• Fig. 19 U.S. anti-venom market: Species outlook and key takeaways
• Fig. 20 Snake market estimates and forecasts, 2018 - 2030
• Fig. 21 Common cobra market estimates and forecasts, 2018 - 2030
• Fig. 22 Common krait market estimates and forecasts, 2018 - 2030
• Fig. 23 Russell viper market estimates and forecasts, 2018 - 2030
• Fig. 24 Others market estimates and forecasts, 2018 - 2030
• Fig. 25 Scorpion market estimates and forecasts, 2018 - 2030
• Fig. 26 Spider market estimates and forecasts, 2018 - 2030
• Fig. 27 Other market estimates and forecasts, 2018 - 2030
• Fig. 28 U.S. anti-venom market: Type movement analysis
• Fig. 29 U.S. anti-venom market: Type outlook and key takeaways
• Fig. 30 Polyvalent market estimates and forecasts, 2018 - 2030
• Fig. 31 Monovalent market estimates and forecasts, 2018 - 2030
• Fig. 32 U.S. anti-venom market: Mode of Action movement analysis
• Fig. 33 U.S. anti-venom market: Mode of Action outlook and key takeaways
• Fig. 34 Cytotoxic market estimates and forecasts, 2018 - 2030
• Fig. 35 Neurotoxic market estimates and forecasts, 2018 - 2030
• Fig. 36 Hemotoxic market estimates and forecasts, 2018 - 2030
• Fig. 37 Cardiotoxic market estimates and forecasts, 2018 - 2030
• Fig. 38 Myotoxic market estimates and forecasts, 2018 - 2030
• Fig. 39 Others market estimates and forecasts, 2018 - 2030
• Fig. 40 U.S. anti-venom market: End Use movement analysis
• Fig. 41 U.S. anti-venom market: End Use outlook and key takeaways
• Fig. 42 Hospitals market estimates and forecasts, 2018 - 2030
• Fig. 43 Clinics market estimates and forecasts, 2018 - 2030
• Fig. 44 Ambulatory surgical centers market estimates and forecasts, 2018 - 2030

U.S. Anti-Venom Market Summary

The U.S. anti-venom market size was estimated at USD 424.5 million in 2024 and is projected to reach USD 670.0 million by 2030, growing at a CAGR of 8.0% from 2025 to 2030. The market is expanding due to the rising incidence of venomous bites and stings, especially from snakes and insects.

Increased human interaction with venomous species is fueled by urbanization, deforestation, and climate change, which have impacted the habitats of these animals and brought them closer to populated areas. This trend has heightened the need for effective anti-venom treatments to reduce fatalities and long-term health complications associated with envenomation, driving the U.S. anti-venom industry.

Advancements in biotechnology significantly contribute to market growth. Innovations such as monoclonal antibody-based anti-venoms and recombinant DNA technologies have resulted in the development of more potent, safer, and targeted therapies. These improvements enhance treatment outcomes and help reduce production costs, making anti-venoms more accessible. The continuous research and development efforts by pharmaceutical companies and research institutions, particularly in the U.S., foster innovation and the introduction of advanced anti-venom products tailored to specific venom types.

The U.S. market benefits from a robust healthcare system that facilitates rapid access to anti-venom treatments in emergency settings. The prevalence of outdoor recreational activities and expanding urban development into wildlife habitats increases the likelihood of encounters with venomous species, thereby driving market demand. Moreover, the presence of key industry players and ongoing government support for pharmaceutical innovation strengthen the market's growth prospects.

U.S. Anti-Venom Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. anti-venom market report based on species, type, mode of action, and end use.

• Species Outlook (Revenue, USD Million, 2018 - 2030)
• Snake
  • Common Cobra
  • Common Krait
  • Russell Viper
  • Others
• Scorpion
• Spider
• Other
• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Polyvalent
• Monovalent
• Mode of Action Outlook (Revenue, USD Million, 2018 - 2030)
• Cytotoxic
• Neurotoxic
• Hemotoxic
• Cardiotoxic
• Myotoxic
• Others
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Clinics
• Ambulatory Surgical Centers

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Species
  • 1.2.2. Type
  • 1.2.3. Mode of action
  • 1.2.4. End use
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Species outlook
  • 2.2.2. Type outlook
  • 2.2.3. Mode of action outlook
  • 2.2.4. End use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Anti-Venom Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Anti-Venom Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. U.S. Anti-Venom Market: Pipeline Analysis

Chapter 4. U.S. Anti-Venom Market: Species Estimates & Trend Analysis

• 4.1. Species Segment Dashboard
• 4.2. U.S. Anti-Venom Market: Species Movement Analysis
• 4.3. U.S. Anti-Venom Market Size & Trend Analysis, by Species, 2018 to 2030 (USD Million)
• 4.4. Snake
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Common Cobra
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Common Krait
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Russell Viper
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Scorpion
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Spider
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Other
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Anti-Venom Market: Type Estimates & Trend Analysis

• 5.1. Type Segment Dashboard
• 5.2. U.S. Anti-Venom Market: Type Movement Analysis
• 5.3. U.S. Anti-Venom Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. Polyvalent
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Monovalent
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Anti-Venom Market: Mode of Action Estimates & Trend Analysis

• 6.1. Mode of Action Segment Dashboard
• 6.2. U.S. Anti-Venom Market: Mode of Action Movement Analysis
• 6.3. U.S. Anti-Venom Market Size & Trend Analysis, by Mode of Action, 2018 to 2030 (USD Million)
• 6.4. Cytotoxic
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Neurotoxic
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Hemotoxic
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Cardiotoxic
  • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Myotoxic
  • 6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Others
  • 6.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Anti-Venom Market: End Use Estimates & Trend Analysis

• 7.1. End Use Segment Dashboard
• 7.2. U.S. Anti-Venom Market: End Use Movement Analysis
• 7.3. U.S. Anti-Venom Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Hospitals
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Clinics
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Ambulatory Surgical Centers
  • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Boehringer Ingelheim
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. CSL Limited
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Merck & Co., Inc.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Pfizer, Inc.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives